Abstract
It is widely accepted that sepsis is a leading cause of mortality for patients admitted to the ICU, and that advances in ICU supportive care and specific antimicrobial therapy have had a relatively modest impact on outcome [1–4]. There is less agreement, however, on what sepsis is, on what alternative therapeutic strategies might be employed to treat it, and on which patients might benefit from these approaches. A recent consensus conference on definitions has emphasized the importance of uniform terminology [5], yet it is not at all certain that standardization of terminology reflects clarification of a complex biologic process.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bone RC, Fisher CJ, Clemmer TP, et al and the Methylprednisolone Severe Sepsis Study Group (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317: 653–658
Ziegler EJ, Fisher CJ, Sprung CL, et al (1991) Treatment of Gram negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 324: 429–436
Bone RC, Fisher CJ, Clemmer TP, et al and the Methylprednisolone Severe Sepsis Study Group (1989) Sepsis syndrome: A valid clinical entity. Crit Care Med 17: 389–393
Parillo JE, Parker MM, Natanson C, et al (1990) Septic shock in humans. Ann Intern Med 113: 227–242
ACCP-SCCM Consensus Conference (1992) Definitions of sepsis and multiple organ failure. Crit Care Med 20: 864–874
Majno G (1991) The ancient riddle of sepsis. J Infect Dis 163: 937–945
Stedman’s Medical Dictionary, 24th Ed. (1982) Williams and Wilkins, Baltimore MD
Dinarello CA, Wolff SM (1993) The role of interleukin-1 in disease. N Engl J Med 328: 106–113
Fasano MB, Cousart S, Neal S, McCall CE (1991) Increased expression of the interleukin 1 receptor on blood neutrophils of humans with the sepsis syndrome. J Clin Invest 88: 1452–1459
Arend WP (1991) Interleukin 1 receptor antagonist. A new member of the interleukin-1 family. J Clin Invest 88: 1445–1451
Lange JR, Alexander HR, Merino MJ, Doherty GM, Norton JA (1992) Interleukin-la prevention of the lethality of Escherichia coli peritonitis. J Surg Res 52: 555–559
Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P (1989) Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17: 975–978
Munoz C, Carlet J, Fitting C, Misset B, Bieriot JP, Cavaillon JM (1991) Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 88: 1747–1754
Luger A, Graf H, Schwarz H-P, Stummvoll K, Luger TA (1986) Decreased serum interleukin-1 activity and monocyte interleukin-1 production in patients with fatal sepsis. Crit Care Med 14: 458–461
Damas P, Ledoux D, Nys M, et al (1992) Cytokine serum level during severe sepsis in humans. IL-6 as a marker of severity. Ann Surg 215: 356–362
Libert C, Vink A, Coulie P, et al (1992) Limited involvement of interleukin-6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin-6 or its receptor in various animal models. Eur J Immunol 22: 2625–2630
Tracey KJ, Cerami A (1993) Tumor necrosis factor: An updated review of its biology. Crit Care Med 21: 5415 - S422
Block MI, Berg M, McNamara MJ, Norton JA, Fraker DL, Alexander HR (1993) Passive immunization of mice against D factor blocks lethality and cytokine release during endotoxemia. J Exp Med 178: 1085–1090
Bernhagen J, Calandra T, Mitchell RA, et al (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxemia. Nature 365: 756–759
Beutler B, Grau GE (1993) Tumor necrosis factor in the pathogenesis of infectious diseases. Crit Care Med 21: S423 - S435
Gerard C, Bruyns C, Marchant A, et al (1993) Interleukin-10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 177: 547–550
Shull MM, Ormsby I, Kier AB, et al (1992) Targeted disruption of the mouse transforming growth factor-ß1 gene results in multifocal inflammatory disease. Nature 359: 693–696
MacLean LD, Mulligan WG, McLean APH, Duff JH (1967) Patterns of septic shock in man: A detailed study of 56 patients. Ann Surg 166: 543–562
McCabe WR, Jackson GG (1962) Gram-negative bacteremia II. Clinical, laboratory, and therapeutic observations. Arch Intern Med 110: 856–864
Wiles JB, Cerra FB, Siegel JH, Border JR (1980) The systemic septic response: Does the organism matter? Crit Care Med 8: 55–60
Deutschman CS, Konstantinides FN, Tsai M, Simmons RL, Cerra FB (1987) Physiology and metabolism in isolated viral septicemia. Further evidence of an organism-independent, host-dependent response. Arch Surg 122: 21–25
Watters JM, Bessey PQ, Dinarello CA, Wolff SM, Wilmore DW (1986) Both inflammatory and endocrine mediators stimulate host responses to sepsis. Arch Surg 121: 179–190
Michie HR, Eberlein TJ, Spriggs DR, Manogue KR, Cerami A, Wilmore DW (1988) Interleukin-2 initiates metabolic responses associated with critical illness in humans. Ann Surg 208: 493–503
Leatherman JW, Schmitz PG (1991) Fever, hyperdynamic shock, and multiple-system organ failure. A pseudo-sepsis syndrome associated with chronic salicylate intoxication. Chest 100: 1391
Marshall JC, Sweeney D (1990) Microbial infection and the septic response in critical surgical illness. Sepsis, not infection, determines outcome. Arch Surg 125: 17–25
Fisher CJ, Opal SM, Dhainaut J-F, et al and the CB0006 Sepsis Syndrome Study Group (1993) Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 21: 318–327
Casey LC, Balk RA, Bone RC (1993) Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119: 771–778
Demling RH, Lalonde CC, Jin LJ, Albes J, Fiori N (1986) The pulmonary and systemic response to recurrent endotoxemia in the adult sheep. Surgery 100: 876–883
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Marshall, J.C. (1994). Infection and the Host Septic Response: Implications for Clinical Trials of Mediator Antagonism. In: Vincent, JL. (eds) Yearbook of Intensive Care and Emergency Medicine 1994. Yearbook of Intensive Care and Emergency Medicine 1994, vol 1994. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-85068-4_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-85068-4_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-57613-6
Online ISBN: 978-3-642-85068-4
eBook Packages: Springer Book Archive